Abstract | BACKGROUND: METHODS AND RESULTS: In 187 patients with DCM, levels of MMP-9, TIMP-1 and B(+) Tn-C in serum as well as B(+) Tn-C and ED-A(+) Fn in tissue were quantified and subjected to univariate analysis. For all serum markers, concentrations above a calculated threshold were associated with decreased survival ( MMP-9: p = 0.008, TIMP-1: p = 0.001, B(+) Tn-C: p < 0.001) and a significantly higher risk to die or undergo transplantation. In tissue, a reexpression of B(+) Tn-C and ED-A(+) Fn could be shown. Protein deposition levels of ≥4.5% for B(+) Tn-C and ≥2.1% for ED-A(+) Fn were associated with a significantly decreased survival (p = 0.001 for B(+) Tn-C, p = 0.031 for ED-A(+) Fn) and an increased risk to die or undergo transplantation. In a multivariate analysis, TIMP-1 is the superior parameter to predict transplantation free survival (p = 0.027). CONCLUSIONS: Serum levels of MMP-9, TIMP-1 and B(+) Tn-C and tissue levels of B(+) Tn-C and ED-A(+) Fn are promising markers for risk assessment. The reoccurrence of ED-A(+) Fn and the availability of a human antibody usable as a vehicle for targeted drug delivery might be the basis for novel therapeutic strategies.
|
Authors | Marcus Franz, Alexander Berndt, Dario Neri, Kerstin Galler, Katja Grün, Christiane Porrmann, Franziska Reinbothe, Gerhard Mall, Peter Schlattmann, André Renner, Hans Reiner Figulla, Christian Jung, Friedhelm Küthe |
Journal | International journal of cardiology
(Int J Cardiol)
Vol. 168
Issue 6
Pg. 5344-51
(Oct 15 2013)
ISSN: 1874-1754 [Electronic] Netherlands |
PMID | 23998545
(Publication Type: Journal Article)
|
Copyright | © 2013. |
Chemical References |
- Biomarkers
- FN1 protein, human
- Fibronectins
- TIMP1 protein, human
- Tenascin
- Tissue Inhibitor of Metalloproteinase-1
- MMP9 protein, human
- Matrix Metalloproteinase 9
|
Topics |
- Adult
- Biomarkers
(blood, metabolism)
- Biopsy
- Cardiomyopathy, Dilated
(metabolism, mortality, pathology)
- Disease Progression
- Extracellular Matrix
(metabolism)
- Female
- Fibronectins
(blood, metabolism)
- Fibrosis
(metabolism, pathology)
- Fluorescent Antibody Technique
- Humans
- Male
- Matrix Metalloproteinase 9
(blood, metabolism)
- Middle Aged
- Myocardium
(metabolism, pathology)
- Prognosis
- Risk Factors
- Tenascin
(blood, metabolism)
- Tissue Inhibitor of Metalloproteinase-1
(blood, metabolism)
- Ventricular Dysfunction, Left
(metabolism, mortality, pathology)
|